시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 헌팅턴병 치료 시장 보고서(2025년)
Huntington´s Disease Treatment Global Market Report 2025
상품코드 : 1760559
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,493,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,386,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,279,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

헌팅턴병 치료 시장 규모는 향후 몇 년 동안 빠르게 성장하여 2029년에는 13억 5,000만 달러에 달할 것으로 예상되며, 연평균 13.0%의 성장률을 보일 것으로 예측됩니다. 이 예측 기간의 성장은 개인 맞춤형 의료에 대한 관심 증가, 디지털 건강 모니터링의 통합 발전, 희귀질환 치료제에 대한 규제 당국의 지원 강화, 증상 치료 치료제에 대한 수요 증가, 질병 조절 치료제에 대한 수요 증가에 의해 주도될 것으로 예측됩니다. 이 기간의 주요 동향으로는 기술 주도형 유전자 침묵 도구의 발전, 세포 기반 치료법 개발, 말초 바이오마커의 출현, 헌팅턴병 치료에 대한 원격 의료의 통합, 환자 보고 결과의 활용, 질병 조절 약물의 지속적인 혁신 등이 있습니다.

헌팅턴병 치료 시장의 성장을 견인할 것으로 예상되는 것은 유전적 원인을 표적으로 삼아 질병의 진행을 늦추는 유전자 치료의 이용 확대입니다. 유전자 치료는 유전자 수준에서 질병을 치료하거나 예방하기 위해 결함이 있는 유전자를 바꾸거나 대체하는 치료법입니다. 정밀의료가 계속 발전하고 있는 가운데, 유전자 치료는 근본적인 유전적 원인을 직접 표적으로 삼을 수 있는 능력을 제공함으로써 기존 치료 대비 치료 결과를 개선할 수 있습니다. 헌팅턴병의 경우, 유전자 치료는 유해 단백질을 생성하는 결함이 있는 HTT 유전자를 침묵시켜 신경세포의 손상을 방지하는 것을 목표로 합니다. 이 접근법은 질병의 진행을 늦추고, 뇌 기능을 보호하며, 장기적으로 질병을 통제할 수 있는 가능성을 제공합니다. 예를 들어, 2023년 7월 미국 유전자 및 세포치료학회(ASGCT)와 씨트라인(Citeline)은 2023년 2분기 말까지 임상 2상 시험 중인 유전자 치료제의 수가 247개에서 260개로 5% 증가했다고 보고했습니다. 이처럼 유전자 치료제 증가가 시장 성장에 기여하고 있습니다.

헌팅턴병 치료 시장은 선택적 소낭 모노아민 수송체 2(VMAT2) 억제제 캡슐과 같이 환자의 삶의 질을 향상시키면서 질병의 진행을 늦추는 것을 목표로 하는 개발에도 집중하고 있습니다. 에 관여하는 단백질을 억제함으로써 작용합니다. 이 약물들은 신경전달물질의 방출을 억제하여 불수의적 운동 및 기타 관련 증상을 조절하는 데 도움이 됩니다. 예를 들어, 뉴로크라인 바이오사이언스는 2023년 8월 성인 헌팅턴병에 수반되는 무도병 치료제로 1일 1회 경구용 VMAT2 억제제인 인그레자(성분명: 바베나딘) 캡슐을 FDA로부터 승인받았습니다. 본 제제는 뇌 내 과도한 도파민 신호전달을 억제하여 불수의적 운동을 억제하는 약물로, 다양한 강도의 캡슐이 구비되어 있어 환자의 편의에 따라 복용방법을 선택할 수 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나재난과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

제36장 부록

LSH
영문 목차

영문목차

Huntington's disease treatment consists of medical therapies aimed at managing the symptoms of this progressive neurological condition. The main objective is to slow the disease's progression, reduce symptoms, and improve the patient's quality of life.

The primary types of treatment for Huntington's disease are symptomatic treatments and disease-modifying therapies. Symptomatic treatments focus on alleviating the symptoms of Huntington's disease and enhancing quality of life, without targeting the underlying cause. These treatments are becoming increasingly sought after as patients look for better ways to manage daily challenges. Various methods are used to administer these treatments, including oral, intravenous, subcutaneous, and topical routes, for applications in genetic, neurological, and psychiatric disorders. These treatments are available through multiple distribution channels, such as hospital pharmacies, retail pharmacies, and online pharmacies, and are used by a wide range of end users, including hospitals, clinics, home care settings, and research institutions.

The Huntington's disease treatment market research report is one of a series of new reports from The Business Research Company that provides Huntington's disease treatment market statistics, including the Huntington's disease treatment industry's global market size, regional shares, competitors with the Huntington's disease treatment market share, detailed Huntington's disease treatment market segments, market trends and opportunities, and any further data you may need to thrive in the Huntington's disease treatment market. This Huntington's disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The Huntington's disease treatment market size has grown rapidly in recent years. It will grow from $0.73 billion in 2024 to $0.83 billion in 2025 at a compound annual growth rate (CAGR) of 13.3%. The growth observed in the historical period can be attributed to several factors, including increased awareness of genetic disorders, improved accessibility to genetic testing, higher investment in neurodegenerative disease research, a rise in the number of clinical trials for experimental therapies, and a growing pipeline of disease-modifying drugs.

The Huntington's disease treatment market size is expected to see rapid growth in the next few years. It will grow to $1.35 billion in 2029 at a compound annual growth rate (CAGR) of 13.0%. The growth in the forecast period is expected to be driven by a stronger focus on personalized medicine, greater integration of digital health monitoring, increased regulatory support for orphan drugs, rising demand for therapies that provide symptomatic relief, and a higher demand for disease-modifying treatments. Key trends during this period are likely to include advancements in technology-driven gene silencing tools, the development of cell-based therapies, the emergence of peripheral biomarkers, the integration of telehealth into Huntington's disease care, the incorporation of patient-reported outcomes, and continued innovation in disease-modifying drugs.

The growth of the Huntington's disease treatment market is expected to be driven by the increasing use of gene therapies, which target genetic causes and slow disease progression. Gene therapies are treatments that alter or replace defective genes to cure or prevent diseases at the genetic level. As precision medicine continues to advance, gene therapies offer the ability to directly target the underlying genetic causes, leading to improved outcomes compared to traditional treatments. In Huntington's disease, gene therapies aim to silence the defective HTT gene that produces harmful proteins, thus preventing nerve cell damage. This approach helps slow disease progression, protect brain function, and provides potential for long-term control. For example, in July 2023, the American Society of Gene & Cell Therapy (ASGCT) and Citeline reported that the number of gene therapies in phase II clinical trials increased by 5% from 247 to 260 by the end of Q2 2023. As such, the increase in gene therapies is contributing to the market's growth.

Companies in the Huntington's disease treatment market are also focusing on the development of advanced therapies, such as selective vesicular monoamine transporter 2 (VMAT2) inhibitor capsules, which aim to improve patient quality of life while slowing disease progression. VMAT2 inhibitors work by blocking a protein involved in packaging neurotransmitters for release in the brain. These drugs reduce neurotransmitter release, helping manage involuntary movements and other related symptoms. For example, in August 2023, Neurocrine Biosciences received FDA approval for Ingrezza (valbenazine) capsules, a once-daily oral VMAT2 inhibitor for the treatment of chorea associated with Huntington's disease in adults. This medication helps control involuntary movements by reducing excessive dopamine signaling in the brain and is available in various strengths, offering a convenient dosing option for patients.

In December 2024, PTC Therapeutics, a US-based pharmaceutical company developing treatments for Huntington's disease, entered into a partnership with Novartis AG to advance the development of PTC518, a potential first-in-class oral, disease-modifying therapy for Huntington's disease. This collaboration aims to accelerate the development and global commercialization of PTC518. Novartis AG, a Switzerland-based pharmaceutical company, specializes in drugs for Huntington's disease.

Major players in the huntington's disease treatment market are F. Hoffmann-La Roche Ltd., Novartis AG, Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Incorporated, Bausch Health Companies Inc., Sun Pharmaceutical Industries Inc., H. Lundbeck A/S, WaVe Life Sciences Ltd., Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals plc, Lupin Limited, Neurocrine Biosciences Inc., Alnylam Pharmaceuticals Inc., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Annexon Inc., Uniqure NV, Sage Therapeutics Inc., Azevan Pharmaceuticals Inc., Prilenia Therapeutics B.V.

North America was the largest region in the Huntington's disease treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in Huntington's disease treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the Huntington's disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The Huntington's disease treatment market consists of sales of products including tetrabenazine, deutetrabenazine, huntingtin-lowering therapies, cannabinoids, and cognitive enhancers. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Huntington's Disease Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on huntington's disease treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for huntington's disease treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The huntington's disease treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Subsegments

Table of Contents

1. Executive Summary

2. Huntington's Disease Treatment Market Characteristics

3. Huntington's Disease Treatment Market Trends And Strategies

4. Huntington's Disease Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Huntington's Disease Treatment Growth Analysis And Strategic Analysis Framework

6. Huntington's Disease Treatment Market Segmentation

7. Huntington's Disease Treatment Market Regional And Country Analysis

8. Asia-Pacific Huntington's Disease Treatment Market

9. China Huntington's Disease Treatment Market

10. India Huntington's Disease Treatment Market

11. Japan Huntington's Disease Treatment Market

12. Australia Huntington's Disease Treatment Market

13. Indonesia Huntington's Disease Treatment Market

14. South Korea Huntington's Disease Treatment Market

15. Western Europe Huntington's Disease Treatment Market

16. UK Huntington's Disease Treatment Market

17. Germany Huntington's Disease Treatment Market

18. France Huntington's Disease Treatment Market

19. Italy Huntington's Disease Treatment Market

20. Spain Huntington's Disease Treatment Market

21. Eastern Europe Huntington's Disease Treatment Market

22. Russia Huntington's Disease Treatment Market

23. North America Huntington's Disease Treatment Market

24. USA Huntington's Disease Treatment Market

25. Canada Huntington's Disease Treatment Market

26. South America Huntington's Disease Treatment Market

27. Brazil Huntington's Disease Treatment Market

28. Middle East Huntington's Disease Treatment Market

29. Africa Huntington's Disease Treatment Market

30. Huntington's Disease Treatment Market Competitive Landscape And Company Profiles

31. Huntington's Disease Treatment Market Other Major And Innovative Companies

32. Global Huntington's Disease Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Huntington's Disease Treatment Market

34. Recent Developments In The Huntington's Disease Treatment Market

35. Huntington's Disease Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기